BRCA1/2 mutations and expression: Response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

BRCA1/2 mutations and expression: Response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer

Published:2012-06 Issue:3 Volume:125 Page:677-682
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Dann Rebecca Byler,DeLoia Julie A.,Timms Kirsten M.,Zorn Kristin K.,Potter Jennifer,Flake Darl D.,Lanchbury Jerry S.,Krivak Thomas C.

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference34 articles.

1. Cancer Statistics, 2010;Jemal;CA Cancer J Clin,2010

2. Prognostic factors for stage II epithelial ovarian cancer: a gynecologic oncology group study;Winter;J Clin Oncol,2007

3. Phase III Trial of Carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study;Ozols;J Clin Oncol,2003

4. Evaluation of new platinum-based treatment regimens in advanced-stage Ovarian Cancer: a phase III trial of the gynecologic cancer intergroup;Bookman;J Clin Oncol,2009

5. Intraperitoneal cisplatin and paclitaxel in ovarian cancer;Armstrong;N Engl J Med,2006

Cited by 104 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Factors associated with an inconclusive result from commercial homologous recombination deficiency testing in ovarian cancer;Cancer;2024-08-16

2. Cell-intrinsic platinum response and associated genetic and gene expression signatures in ovarian cancer cell lines and isogenic models;2024-07-29

3. Outcomes of secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer progressed after prior poly (adenosine diphosphate-ribose) polymerase inhibitors: A retrospective cohort study;European Journal of Surgical Oncology;2024-07

4. Cisplatin in the era of PARP inhibitors and immunotherapy;Pharmacology & Therapeutics;2024-06

5. Discovery of Novel Potential Prognostic Markers and Targeted Therapy to Overcome Chemotherapy Resistance in an Advanced-Stage Wilms Tumor;Cancers;2024-04-19

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3